Sandoz Group AG Asset Resilience Ratio
Sandoz Group AG asset resilience ratio. Sandoz Group AG (SDZ) has an Asset Resilience Ratio of 7.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Sandoz Group AG balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sandoz Group AG (2023–2025)
Asset resilience ratio of Sandoz Group AG from 2023 to 2025. This chart shows how Sandoz Group AG's Asset Resilience Ratio has changed over time. See SDZ cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Sandoz Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sandoz Group AG asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF1.74 Billion | 7.89% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF1.74 Billion | 7.89% |
Asset Resilience Insights
- Limited Liquidity: Sandoz Group AG maintains only 7.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Sandoz Group AG Industry Peers by Asset Resilience Ratio
Compare Sandoz Group AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Sandoz Group AG Asset Resilience Ratio by Year (2023–2025)
Sandoz Group AG asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Sandoz Group AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.89% | CHF1.74 Billion ≈ $2.20 Billion |
CHF22.03 Billion ≈ $27.85 Billion |
+1.91pp |
| 2024-12-31 | 5.98% | CHF1.19 Billion ≈ $1.51 Billion |
CHF19.91 Billion ≈ $25.17 Billion |
+1.18pp |
| 2023-12-31 | 4.80% | CHF933.39 Million ≈ $1.18 Billion |
CHF19.43 Billion ≈ $24.56 Billion |
-- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more